XTL Announces Receipt of Staff Delist Determination from Nasdaq
Rhea-AI Summary
XTL Biopharmaceuticals (Nasdaq:XTLB) received a Nasdaq Staff letter dated May 18, 2026, stating it is noncompliant with Listing Rule 5250(c)(1) for not filing its 2025 Form 20-F on time.
This adds to existing issues on minimum $2.5 million stockholders’ equity and $1 bid price, which the Nasdaq Hearings Panel will review.
Positive
- Company may present written views to the Nasdaq Hearings Panel by May 26, 2026
- Company intends to request an extension of the stay of suspension by May 26, 2026
Negative
- Nasdaq Staff added late 2025 Form 20-F filing as a delisting basis
- Existing deficiencies in $2.5 million stockholders’ equity and $1 minimum bid price
- Risk of suspension and delisting from The Nasdaq Capital Market remains
- No assurance of extended stay or continued listing from the Panel
News Market Reaction – XTLB
In the May 26 session, XTLB declined 5.18%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.3% during that session. Argus tracked a trough of -31.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Acquisition announcement | Positive | +54.8% | Agreed all-stock acquisition of Psyga Bio with substantial new pipeline assets. |
| Mar 20 | ADS ratio change | Neutral | -1.2% | One-for-four reverse ADS split via ratio change to support bid price. |
| Feb 27 | Delist determination | Negative | +0.3% | Nasdaq staff deemed company a public shell and cited listing deficiencies. |
| Jan 29 | Strategic update | Positive | +1.7% | Planned NeuroNOS acquisition and private placement to address equity deficit. |
| Jan 23 | Equity deficiency | Negative | -10.1% | Nasdaq notice of $47,000 equity deficit vs $2.5M minimum requirement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News around Nasdaq compliance and capital structure has been frequent; most such updates led to price moves broadly consistent with the tone, with one notable divergence on a prior delisting notice.
Over the last six months, XTLB’s news flow has centered on Nasdaq compliance and strategic transactions. An April 29, 2026 Psyga Bio acquisition announcement saw a strong +54.78% reaction. Multiple 2026 items detailed equity deficits, minimum bid price issues, and a public-shell delisting determination, with reactions ranging from -10.08% to modest gains. Today’s additional delisting basis (late Form 20‑F for 2025) extends this pattern of listing risk, against a backdrop of transactions aimed at restoring compliance.
Key Terms
form 20-f regulatory
listing rule 5250(c)(1) regulatory
listing rule 5550(a)(2) regulatory
nasdaq hearings panel regulatory
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated May 18, 2026, notifying the Company that since the Company has not yet filed its Annual Report on Form 20-F for the year ended December 31, 2025, it no longer complies with Nasdaq’s Listing Rule Listing Rule 5250(c)(1) which requires companies to timely file all required periodic financial reports with the SEC.
Nasdaq informed the Company that this matter serves as an additional basis for delisting the Company’s securities from Nasdaq and that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in its decision regarding the Company’s continued listing on The Nasdaq Capital Market. In that regard, the Company may present its views with respect to this additional deficiency to the Panel in writing no later than May 26, 2026. In addition, since, as previously disclosed by the Company, the Company is already before a Panel for its failure to comply with the minimum
The Company intends to request to extend the stay of the suspension of its securities from The Nasdaq Capital Market by May 26, 2026. There can be no assurance that the Panel will accept the Company’s view on this matter grant the extended stay or grant the Company’s request for continued listing.
About XTL Biopharmaceuticals Ltd.
XTL is an IP Portfolio company that holds an IP portfolio including hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) that the company sublicenses. The company actively pursues strategic collaborations and acquisitions to expand its therapeutic portfolio into high-value disease areas.
XTL is traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA).
Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) the Company’s ability to successfully manage and integrate any joint ventures, acquisitions of businesses, solutions or technologies; (ii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iii) the ability to attract and retain qualified employees and key personnel; (iv) adverse effects of increased competition on the Company’s future business; (v) the risk that changes in consumer behavior could adversely affect the Company’s business; (vi) the Company’s ability to protect its intellectual property; (vii) the Company’s ability to successfully consummate the acquisition of outstanding shares of PsygaBio Ltd., and, if consummated, to successfully manage and integrate Psyga; and (viii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent registration statement on Form F-1 and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972 3 611 6666
Email: info@xtlbio.com
www.xtlbio.com
